Form 4: Pulmonx Director Tiffany Sullivan Receives RSU Grant

Director Tiffany Sullivan was granted 40,000 restricted stock units in Pulmonx Corporation.

Summary

• Director Tiffany Sullivan acquired 40,000 restricted stock units (RSUs) of Pulmonx Corporation common stock.
• The transaction occurred on June 5, 2026.
• The RSUs were granted at a price of $0 per share.
• Following this transaction, the reporting person's total beneficial ownership is 115,199 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to time-based conditions, specifically the earlier of the one-year anniversary of the grant or the next annual meeting of stockholders.

Future Outlook

The RSUs vest on the earlier of the one-year anniversary of the grant (June 5, 2027) or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize board members and align their interests with those of the shareholders.

Comparison to Industry Standards

• The use of RSU grants for director compensation is consistent with standard practices for mid-cap medical device companies.
• The vesting schedule aligns with typical one-year director term cycles.

Stakeholder Impact

• Shareholders may view the equity grant as a standard alignment of director incentives.

Next Steps

• Vesting of the 40,000 RSUs on June 5, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Pulmonx, LUNG, Form 4, Insider Trading, Director Compensation, Restricted Stock Units